08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Free fatty acid receptor 2 (FFAR2; GPR43); FFAR3 (GPR41)

Endocrine/metabolic disease INDICATION: Diabetes Cell culture and mouse studies suggest FFAR2 and FFAR3 antagonists could help treat type 2 diabetes. In mouse and human β cell lines, agonizing FFAR2 and FFAR3 with acetate decreased insulin secretion compared...
08:00 , Nov 6, 2008 |  BC Innovations  |  Targets & Mechanisms

The long and short of fat

With patent protection for Roche'sXenical orlistat set to expire in 2009, the obesity drug's $531 million in 2007 sales will soon be up for grabs. Now, two mouse studies make a case for blocking receptors...
08:00 , Nov 6, 2008 |  BC Innovations  |  Targets & Mechanisms

The long and short of fat

With patent protection for Roche'sXenical orlistat set to expire in 2009, the obesity drug's $531 million in 2007 sales will soon be up for grabs. Now, two mouse studies make a case for blocking receptors...
08:00 , Nov 6, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease ...